‡ In these countries please contact our distributor

Smith & Nephew announces full commercial release of JOURNEY™ II XR Total Knee Arthroplasty

6 March 2018

Smith & Nephew, (LSE:SN, NYSE:SNN), the global medical technology business, today announces the full commercial release of bi-cruciate retaining JOURNEY II XR total knee arthroplasty (TKA) in the United States and Japan.

JOURNEY II XR is the next step in the evolution of total knee replacement surgery. By retaining, rather than substituting, the anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL), JOURNEY II XR is designed to combine the greater patient satisfaction of a partial knee replacement with the long-term survivorship and reproducible principles of TKA1-2. JOURNEY II XR accomplishes this by eliminating the past concerns of bi-cruciate retaining knees through:

  • An implant design that reflects more accurate replication of the knee anatomy3
  • A robust tibial baseplate designed for optimal fixation and fatigue strength
  • The application of Smith & Nephew’s VERILAST™ Technology, an advanced bearing surface designed to provide lasting survivorship4
  • The introduction of enabling technologies such as NAVIO™ robotics-assisted surgery and VISIONAIRE™ patient matched adaptive guides to help deliver highly reproducible outcomes

Mike Donoghue, Senior Vice President, Global Orthopaedic Marketing said, 

“The JOURNEY II XR knee offers surgeons an innovative treatment option for arthritic patients who have intact and well-functioning cruciate ligaments. The retention of the cruciate ligaments may provide patients with more normal feel and stability throughout the range of motion, and may lead to a smoother recovery, improved function, and better patient satisfaction.”3,6-8

JOURNEY II total knee system is designed to achieve normal shapes, position and motion. Smith & Nephew created this platform to empower patients to “rediscover normal” following total knee arthroplasty. The full commercial release of JOURNEY II XR follows a successful limited market release in both the United States and Japan with more than 70 surgeons in both countries implanting over 1,100 JOURNEY II XR knees during the last 18 months9. Join Smith & Nephew at the American Academy of Orthopaedic Surgeons Annual Meeting, Booth #1651 in New Orleans, LA, March 7-10 to explore The Power of Patient Satisfaction and elevate what’s possible with the JOURNEY II XR Knee system.  




Charles Reynolds

+44 (0) 1923 477314

Smith & Nephew


Dave Snyder

+1 (978) 749-1440

Smith & Nephew



1.Patient satisfaction after primary total and unicompartmental knee arthroplasty: an age-dependent analysis. Von Keudell, Sodha, Collins, Minas, Fitz, Gomoll; Knee. 2014 Jan;21(1):180-4.
2.Total knee replacement with retention of both cruciate ligaments: a 22-year follow-up study. P. Sabouret, F. Lavoie, J-M Cloutier Bone Joint J. 2013 Jul; 95-B(7): 917–922.
3.Short-term Range of Motion is Increased after TKA with an asymmetric bicruciate stabilized implant.Accepted Poster Presentation, AAOS 2018 New Orleans. Kaitlin M. Carroll, Peter K. Sculco, Brian CMichaels,Richard L. Murphy, Seth A, Jerabek, David J. Mayman.
4. Testing concluded at 45 million cycles, ISO 14242-1 and 14243-3 define test completion at 5 million cycles.
5. Hommel, Hagen, and Kai Wilke. “Good Early Results Obtained with a Guided-Motion Implant for Total Knee Arthroplasty: A Consecutive Case Series.” The Open Orthopaedics Journal 11 (2017): 51–56. PMC. Web. 27 Sept. 2017.
6. Kaneko, Takao et al. Bi-cruciate substituting total knee arthroplasty improved medio-lateral instability in mid-flexion range. Journal of Orthopaedics. 14. 201-206. 10.1016.
7. Grieco, Trevor F., et al. “In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy.” The Journal of Arthroplasty, 2017, doi:10.1016/j.arth.2017.09.035.
8. Iriuchishima, Takanori, and Keinosuke Ryu. “A Comparison of Rollback Ratio between Bicruciate Substituting Total Knee Arthroplasty and Oxford Unicompartmental Knee Arthroplasty.” The Journal of Knee Surgery, 2017, doi:10.1055/s-0037-1604445.
9. Data on file with Smith & Nephew.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website, follow @SmithNephewplc on Twitter or visit SmithNephewplc on

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.